methionine has been researched along with alendronate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Duque, G; Rivas, D; Vidal, C | 1 |
| Gupta, S; Khandelwal, M; Manglani, K; Surolia, A; Vijayan, V | 1 |
| Channa, IS; Hashim, Z; Ilyas, A; Zarina, S | 1 |
1 review(s) available for methionine and alendronate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for methionine and alendronate
| Article | Year |
|---|---|
Protein isoprenylation regulates osteogenic differentiation of mesenchymal stem cells: effect of alendronate, and farnesyl and geranylgeranyl transferase inhibitors.
Topics: Alendronate; Alkyl and Aryl Transferases; Benzamides; Bone Density Conservation Agents; Cell Differentiation; Cell Nucleus; Enzyme Inhibitors; Farnesyltranstransferase; Humans; In Vitro Techniques; Male; Mesenchymal Stem Cells; Methionine; Osteoblasts; Osteogenesis; Protein Prenylation | 2011 |
Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis.
Topics: Acid Phosphatase; Administration, Oral; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Chemokine CCL3; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Female; Inflammation Mediators; Isoenzymes; Methionine; Myeloid Differentiation Factor 88; NF-kappa B; Osteoclasts; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; RNA Interference; Signal Transduction; Tartrate-Resistant Acid Phosphatase; Time Factors; Toll-Like Receptor 4 | 2014 |
Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study.
Topics: Alendronate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Methionine; Proteomics; Signal Transduction; Tandem Mass Spectrometry; Time Factors | 2018 |